Extended N-Arylsulfonylindoles as 5-HT6 Receptor Antagonists: Design, Synthesis & Biological Evaluation

Extended N-Arylsulfonylindoles as 5-HT6 Receptor Antagonists: Design, Synthesis & Biological Evaluation

Based on a known pharmacophore model for 5-HT6 receptor antagonists, a series of novel extended derivatives of the N-arylsulfonyindole scaffold were designed and identified as a new class of 5-HT6 receptor modulators. Eight of the compounds exhibited moderate to high binding affinities and displayed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalo Vera, Carlos F. Lagos, Sebastián Almendras, Dan Hebel, Francisco Flores, Gissella Valle-Corvalán, C. David Pessoa-Mahana, Jaime Mella-Raipán, Rodrigo Montecinos, Gonzalo Recabarren-Gajardo
Formato:	Artículo
Lenguaje:	English
Publicado:	MDPI AG 2016-08-01
Colección:	Molecules
Materias:	arylsulfonylindole 5-HT6 receptor antagonists binding affinity arylpiperazines
Acceso en línea:	http://www.mdpi.com/1420-3049/21/8/1070

Ejemplares similares

Novel <i>N</i>-Arylsulfonylindoles Targeted as Ligands of the 5-HT<sub>6</sub> Receptor. Insights on the Influence of C-5 Substitution on Ligand Affinity
por: Loreto Arrieta-Rodríguez, et al.
Publicado: (2021-06-01)

Design of an innovative nanovehicle to enhance brain permeability of a novel 5-HT6 receptor antagonist
por: María Javiera Alvarez-Figueroa, et al.
Publicado: (2024-12-01)

Synthesis and Bioactivity Evaluation of N-Arylsulfonylindole Analogs Bearing a Rhodanine Moiety as Antibacterial Agents
por: Ming-Xia Song, et al.
Publicado: (2017-06-01)

Influence of N–1 substituent properties on binding affinities of arylpiperazines to the binding site of 5-HT1A receptor
por: MARIO V. ZLATOVIC, et al.
Publicado: (2006-11-01)

Influence of N-1 substituent properties on binding affinities of arylpiperazines to the binding site of 5-HT1A receptor
por: Zlatović Mario V., et al.
Publicado: (2006-01-01)

New, Eco-Friendly Method for Synthesis of 3-Chlorophenyl and 1,1′-Biphenyl Piperazinylhexyl Trazodone Analogues with Dual 5-HT<sub>1A</sub>/5-HT<sub>7</sub> Affinity and Its Antidepressant-like Activity
por: Przemysław Zaręba, et al.
Publicado: (2022-10-01)

Synthesis, computational and pharmacological evaluation of novel N-{4-[2-(4-aryl-piperazin-1-yl)ethyl]phenyl}-arylamides
por: Andrić Deana B., et al.
Publicado: (2024-01-01)

3D-QSAR modeling and pharmacophore study of serotonin 5HT-₂A receptors antagonists
por: Antonijević Mirjana, et al.
Publicado: (2017-01-01)

Investigation of key interactions between the second extracellular loop of dopamine D2 receptor and several hydroxy-N-{[2-(4-phenyl-piperaziny-1-yl)ethyl]phenyl}-nicotinamides
por: Šukalović Vladimir, et al.
Publicado: (2014-01-01)

Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis
por: Daichi Watanabe, et al.
Publicado: (2024-07-01)

Synthesis and Structure-Activity Relationship Analysis of 5-HT7 Receptor Antagonists: Piperazin-1-yl Substituted Unfused Heterobiaryls
por: Lucjan Strekowski, et al.
Publicado: (2016-03-01)

HEMORHEOLOGICAL PROPERTIES OF THE 5-HT2A-ANTAGONIST OF THE 2-METHOXYPHENYL-IMIDAZOBENZIMIDAZOLE DERIVATIVE OF THE RU-31 COMPOUND AND CYPROHEPTADINE, IN COMPARISON WITH PENTHOXYPHYLLINE
por: D. S. Yakovlev, et al.
Publicado: (2021-03-01)

Design, Synthesis and Biological Evaluation of Novel N-Arylpiperazines Containing a 4,5-Dihydrothiazole Ring
por: Giorgia Andreozzi, et al.
Publicado: (2023-10-01)

Pharmacological evaluation of novel 5-HT 3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery
por: Deepali Gupta, et al.
Publicado: (2015-01-01)

Microwave-Assisted Synthesis of Trazodone and Its Derivatives as New 5-HT<sub>1A</sub> Ligands: Binding and Docking Studies
por: Jolanta Jaśkowska, et al.
Publicado: (2019-04-01)

Arylpiperazine Derivatives and Cancer: A New Challenge in Medicinal Chemistry
por: Giorgia Andreozzi, et al.
Publicado: (2024-10-01)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Richard G.W. Proudman, et al.
Publicado: (2022-04-01)

Design, Synthesis and 5-HT<sub>1A</sub> Binding Affinity of <i>N</i>-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)tricyclo[3.3.1.1<sup>3,7</sup>]decan-1-amine and <i>N</i>-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)-3,5-dimethyl-tricylo[3.3.1.1<sup>3,7</sup>]decan-1-amine
por: Grigoris Zoidis, et al.
Publicado: (2022-03-01)

Binding and functional structure-activity similarities of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues at 5-HT2A and 5-HT2B serotonin receptors
por: Prithvi Hemanth, et al.
Publicado: (2023-01-01)

Design, Sustainable Synthesis and Biological Evaluation of a Novel Dual α2A/5-HT7 Receptor Antagonist with Antidepressant-Like Properties
por: Vittorio Canale, et al.
Publicado: (2021-06-01)

6-[2-(4-Arylpiperazin-1-yl)ethyl]-4-halo-1,3-dihydro-2H-benzimidazole-2-thiones: synthesis and pharmacological evaluation
por: DEANA ANDRIC, et al.
Publicado: (2007-08-01)

6-[2-(4-arylpiperazin-1-yl)ethyl]-4-halo-1,3-dihydro-2h-benzimidazole-2-thiones: Synthesis and pharmacological evaluation
por: Andrić Deana, et al.
Publicado: (2007-01-01)

Synthesis of novel 2-(piperazino-1-yl-alkyl)-1H-benzimidazole derivates and assessment of their interactions with the D2 dopamine receptor
por: Penjišević Jelena Z., et al.
Publicado: (2019-01-01)

Synthesis, bioactivity, and molecular docking of novel arylpiperazine derivatives as potential AR antagonists
por: Yueheng Qi, et al.
Publicado: (2022-08-01)

A new approach to ‘on-demand’ treatment of lifelong premature ejaculation by treatment with a combination of a 5-HT1A receptor antagonist and SSRI in rats
por: Jocelien D. A. Olivier, et al.
Publicado: (2023-09-01)

Antiemetic Prophylaxis with Fosaprepitant and 5-HT3-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
por: Cabanillas Stanchi KM, et al.
Publicado: (2020-09-01)

Azologization of serotonin 5-HT3 receptor antagonists
por: Karin Rustler, et al.
Publicado: (2019-03-01)

In Vitro, In Vivo and In Silico Characterization of a Novel Kappa-Opioid Receptor Antagonist
por: Kristina Puls, et al.
Publicado: (2022-05-01)

Structure-Activity Relationships of Substituted 2,3,4,4a,5,10b-Hexahydro-benz[h]isoquinoline-6(1H)-ones as 5-HT2c Receptor Antagonists
por: Heinz Stadler, et al.
Publicado: (2000-11-01)

Structure-Activity Relationships of Substituted 2,3,4,4a,5,10b-Hexahydro-benz[h]isoquinoline-6(1H)-ones as 5-HT2c Receptor Antagonists
por: Heinz Stadler, et al.
Publicado: (2000-11-01)

Design, Synthesis, and Antidepressant Activity Study of Novel Aryl Piperazines Targeting Both 5-HT1A and Sigma-1 Receptors
por: Yan-Na Ni, et al.
Publicado: (2021-12-01)

Anxiolytic-like activity of serotonin-3 receptor antagonist: In-silico molecular modeling, drug-likeness and evaluation of anxiolytic activity
por: Venkatesha Perumal Ramachandran, et al.
Publicado: (2022-06-01)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptors
por: Richard G. W. Proudman, et al.
Publicado: (2020-08-01)

Synthesis, Docking Studies and Pharmacological Evaluation of Serotoninergic Ligands Containing a 5-Norbornene-2-Carboxamide Nucleus
por: Rosa Sparaco, et al.
Publicado: (2022-10-01)

Design, Synthesis and Biological Activity Evaluation of Arylpiperazine Derivatives for the Treatment of Neuropathic Pain
por: Guisen Zhang, et al.
Publicado: (2011-07-01)

5-HT3 and 5-HT4 antagonists inhibit peristaltic contractions in guinea-pig distal colon by mechanisms independent of endogenous 5-HT
por: Tiong Cheng Sia, et al.
Publicado: (2013-08-01)

Identification of Optically Active Pyrimidine Derivatives as Selective 5-HT2C Modulators
por: Juhyeon Kim, et al.
Publicado: (2017-08-01)

Atypical sympathomimetic drug lerimazoline mediates contractile effects in rat aorta predominantly by 5-HT2A receptors
por: Eldina Rizvić, et al.
Publicado: (2017-08-01)

5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
por: Neyousha Mohammadi, et al.
Publicado: (2010-01-01)

5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
por: Neyousha Mohammadi, et al.
Publicado: (2010-01-01)